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Department of Medicine, University Medical Centre Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, GermanyThe question of how much invasiveness is required for diagnos-
ing liver disease and recognizing cirrhosis is highly relevant for
patients, clinicians, and health economists. When a few years
ago I suggested to Thierry Poynard that we compare laparoscop-
ically guided liver biopsy with non-invasive testing, he was
enthusiastic because, in his words, laparoscopy is the Rolls Royce
(or Mercedes Benz) of liver diagnosis. We have not yet managed
to organize the study discussed then, and are thus stuck with the
present controversy – but I agree, laparoscopy is as good as a
Rolls Royce; However, it is cheaper and more versatile, and with
the advent of minimally invasive laparoscopy (mini-laparoscopy)
the technique has the cost of a Volkswagen, the comfort of a
Citroen, the safety of a Volvo, and the reliability of a Mercedes,
all with the gain of information of a modern GPS navigation sys-
tem included.
While I was writing this article, a patient was on my ward
with decompensated alcoholic liver disease. She had a bilirubin
of 5 mg/dl, an INR of three and ascites. Her ﬁbroscan showed a
score of 23 kPa [1]. Was this an obvious case of advanced cirrho-
sis? In mini-laparoscopy, we saw a swollen fatty liver but no nod-
ules. A biopsy revealed an extremely fatty liver with a moderately
severe alcoholic hepatitis, only moderate ﬁbrosis, and no cirrho-
sis. Does this make a difference? Yes, as she is now being treated
with acetylcysteine and steroids, and she is already improving. In
addition, as hope represents such an important ‘‘drug’’ in all
aspects of medicine, we made sure to deliver it in large amounts
to motivate this nice lady who recently lost her loving husband,
to stop drinking alcohol, and to undergo psychiatric treatment.
Fibroscan, by the way, will help me monitor the expected
improvement of her liver, since the resolution of inﬂammation
and removal of fat from the liver will result in lower stiffness
values.
I was less fortunate with another very recent patient of mine.
He was a genotype 1 hepatitis C patient at the age of 58 with no
additional risk factors. Diligent as I am in making a reliable and
aggressive diagnosis, he underwent liver biopsy prior to the initi-
ation of standard PEG-interferon and ribavirin therapy, but for
various reasons biopsy was performed percutaneously using a
Menghini-needle: the histology showed moderately active hepa-
titis C and stage 3 ﬁbrosis. Unfortunately, he failed to respond to
treatment, which was, therefore, stopped after three months. As
he lived a good distance away, we then lost touch with him untilJournal of Hepatology 20
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non-responders. He came to the clinic reporting good health. He
had just retired as a school teacher, had a new girlfriend, and was
looking forward to a happy retirement period. However, his
screening laboratory showed an AFP value of 1435 ng/ml, which
was quickly explained by advanced HCC with lung metastases.
Disease progressed despite local chemoembolization and sys-
temic sorafenib therapy and the patient died a few months later.
Had I performed a mini-laparoscopy at the initial diagnosis, I
would most probably have seen the cirrhosis, we would then
have undertaken a systematic screening programme and we
probably would have recognized this AFP-positive HCC early
enough for curative treatment.
Are these just isolated cases? All cases are unique, and the list
of examples I could present would be very long. When confronted
with liver disease, we would need to know the cause, the activity
and the degree of ﬁbrosis. All three aspects are best answered by
a liver biopsy under macroscopic control. With the exception of
viral hepatitis, there are few liver diseases that can be diagnosed
by laboratory tests alone, and there is no patient, in whom labo-
ratory tests alone can answer the question of whether the
increase of liver enzymes is really due to the suspected causative
agent. Alcohol is the most important factor determining the prog-
nosis in hepatitis C [2], and this can best be assessed by histology.
Co-morbidity due to co-existing conditions such as NASH, alpha-
1 antitrypsin deﬁciency, iron overload, or rare co-incidences such
as schistosomiasis or sarcoidosis may be detected by biopsy and
have very relevant therapeutic consequences [3–6]. Thus, even in
an apparently obvious liver disease, biopsy often reveals impor-
tant surprises. This is all the more the case if clinical and labora-
tory examinations do not make a deﬁnite diagnosis.
Biopsy is the most important cornerstone in the detection and
differentiation of the causes of liver disease. Biopsy is good, but
not excellent, for the staging of liver disease. Sampling error,
small biopsies, fractured biopsies, or irregular cirrhosis may all
account for an under-diagnosis of cirrhosis by percutaneous or
transjugular liver biopsy. Several studies have demonstrated very
reliably that the macroscopic assessment of the liver surface by
laparoscopy will detect 30% more cases of cirrhosis cases than
will liver biopsy alone [7]. This ﬁnding was recently conﬁrmed
by us in a randomized trial comparing mini-laparoscopy with
percutaneous liver biopsy in 857 patients [8]. In addition, mini-
laparoscopy proved to be at least as safe as a percutaneous biopsy
– and probably much safer than a case of unrecognized cirrhosis,
or being treated for the wrong disease. The cost of the procedure11 vol. 54 j 584–585
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is low and easily offset by the health beneﬁt resulting from the
added information.
If I had chronic liver disease, I would like to know if I have cir-
rhosis. Of course, knowing does not mean guessing, and all non-
invasive tests have signiﬁcant false positive and false negative
rates; inevitably, these will result in worrisome wrong diagnoses,
inadequate counselling, and the misallocation of health care
resources, which are all much more costly than the test – and
more risky as well. Even the best study of Fibroscan found a
kPa of 15 or higher only in 85 out of 120 (thus missing 35/120 cir-
rhotics), but at the same time diagnosed a non-existent cirrhosis
in 45 (out of 655) patients [9]. Would you prefer to be amongst
the false positives or amongst the false negatives?
With a French counterpart in this debate, I do not want to
stick to cars as a comparison: if you want to know the Louvre,
what information would you consider adequate: a thoughtful
article in a newspaper (laboratory tests including a ﬁbrotest)?
The Wikipedia article (laboratory tests including a ﬁbrotest plus
ﬁbroscan)? Or would you prefer a good catalogue of the museum
with its explanatory notes (a liver biopsy assessed by an expert
pathologist)? Personally, I would visit the museum and buy a cat-
alogue to help me interpret my personal impressions (laparos-
copy and biopsy). I much prefer the personal visit to the
museum: the Louvre is worth it – and your patients with liver
disease are also worth it.Journal of Hepatology 201References
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